Sleep technology provider HoneyNaps has raised USD 11.6 million in a Series B funding round. The lead investor(s) were not disclosed, but the company noted that several local and foreign investors participated in the round. This brings the total funds raised by the company to USD 16.2 million.
HoneyNaps plans to utilize this new injection of funds to strengthen its foothold in South Korea and the US. The company additionally plans on expanding the capabilities of its platform, hoping to advance its AI for applications in other critical areas such as cardiovascular disease, dementia, and Parkinson’s disease.
Based in South Korea and Massachusetts, HoneyNaps provides an AI-based sleep technology platform to help users diagnose and address sleep disorders. The platform, SOMNUM, uses deep learning to conduct real-time analysis of multi-channel biosignals such as body temperature, heart rate, and respiratory data, providing rapid and accurate diagnostic information for healthcare providers. The platform received FDA approval in 2023 and can be integrated into several preventive and corrective healthcare applications.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.